Viva Biotech Holdings Balance Sheet Health
Financial Health criteria checks 3/6
Viva Biotech Holdings has a total shareholder equity of CN¥3.6B and total debt of CN¥2.9B, which brings its debt-to-equity ratio to 78.9%. Its total assets and total liabilities are CN¥8.1B and CN¥4.5B respectively. Viva Biotech Holdings's EBIT is CN¥290.1M making its interest coverage ratio 1.8. It has cash and short-term investments of CN¥1.1B.
Key information
78.9%
Debt to equity ratio
CN¥2.87b
Debt
Interest coverage ratio | 1.8x |
Cash | CN¥1.07b |
Equity | CN¥3.64b |
Total liabilities | CN¥4.51b |
Total assets | CN¥8.15b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VBIZ.F's short term assets (CN¥2.2B) do not cover its short term liabilities (CN¥3.2B).
Long Term Liabilities: VBIZ.F's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥1.4B).
Debt to Equity History and Analysis
Debt Level: VBIZ.F's net debt to equity ratio (49.4%) is considered high.
Reducing Debt: VBIZ.F's debt to equity ratio has increased from 51.3% to 78.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable VBIZ.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: VBIZ.F is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 1.3% per year.